Kornimate/medical-research-clean huggingface dataset:
effects of functional exercise program with strength load and resistance in children and adolescents with cerebral palsy

Conditions: Cerebral Palsy

Summary: this research project aims to evaluate the benefits of a functional exercise program with strength and resistance load in adolescents with cerebral palsy (cp), specifically classifiedat levels iii and iv of the gross motor function classification system (gmfcs) scale. participants will be included into control or intervention group in this randomized controlled trial. changes in functional percentile, quality of life, and participation in daily environments will be analyzed based on scores obtained with validated assesment scales. the study will be conducted at the children's neurorehabilitation unit of hospitalarias foundation in valencia, with an 18-week intervention plus a 6-month follow-up. this project seeks to provide evidence on rehabilitation strategies that promote autonomy and social inclusion for this population.

this research project is a randomized controlled trial designed to analyze the effects of a functional exercise program with strength and resistance load in adolescents with cp specifically classified at levels iii and iv of the gmfcs scale. the study will include around 40 participants aged 10 to 18 years, randomly assigned to either an intervention group or a control group. the intervention group will perform functional exercises with progressive strength and resistance load, adjusted based on heart rate. the control group will perform the same functional exercises but without any load. the protocol includes 36 sessions over 18 weeks, with evaluations at three key time points: before the intervention, at the end of the protocol, and six months post-intervention. the primary outcomes include functional percentile within the gmfcs, quality of life asperceived by patients and caregivers, and participation in daily environments. the study will adhere to consort guidelines and the declaration of helsinki and has been reviewed by an ethics committee.

Eligibility criteria:
inclusion criteria: * adolescents aged 10 to 18 years. * diagnosis of spastic cerebral palsy (cp). * classification at levels iii or iv of the gmfcs scale. exclusion criteria: * multilevel surgery with osteotomy within the last 12 months. * microtenotomies or percutaneous needle lengthening (apai) within the last 9months. * botulinum toxin injections within the last 3 months. * participation in specific strength training protocols. * lack of cognitive ability to perform the intervention protocol activities.

Keywords: functional exercise strength resistance children adolescents
distal rectus femoris transfer as a part of multilevel surgery in children with spastic diplegia

Conditions: Cerebral Palsy

Summary: the purpose of this study is to evaluate the effects of an additional distal rectus femoris transfer carried out as a part of single-event multilevel surgery in children with spastic diplegic cerebral palsy.


Eligibility criteria:
inclusion criteria: * cerebral palsy * spastic diplegia * ambulatory * stiff knee gait exclusion criteria: * relevant previous surgery at the legs * botulinum-toxin-injections 6 months prior surgery

Keywords: cerebral palsy distal rectus femoris transfer stiff knee gait pattern gait analysis single event multilevel surgery randomized trial crouch gait
precision chemotherapy based on organoid drug sensitivity for colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage iv colorectal cancer.

fluorouracil-based chemotherapy is the standard treatment for stage iv colorectal cancer patients. however, the effects of chemotherapy remains limited. patient-derived tumor organoids are increasingly used as tools for drug test and predicting drug response in the clinic, and have been showed to faithfully predict clinical outcomes of patients with crc. a prospective clinical trial is needed to validate whether the in vitro sensitivity to chemotherapy regimens in organoids drug test is associated with a longer pfs in stage iv colorectal cancer.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 * histological confirmed colorectal cancer * stage iv * american society of anesthesiologists (asa) score i\~iii * no contraindication for chemotherapy * no evidence of other malignant tumor exclusion criteria: * refusing chemotherapy * pregnant or breast-feeding women * severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy

Keywords: organoid drug test
dexmedetomidine complement treats chronic insomnia and improves circadian rhythm (doctor)

Conditions: Chronic Insomnia

Summary: it has been reported that dexmedetomidine, alpha-2 adrenoceptor agonist, can activate endogenous neural sleep pathways in the central nervous system. this randomised, double-blinded and controlled trial was designed to investigate whether dexmedetomidine can improve/treat chronic insomnia patients. its effects on sleep quality and improvement, eeg and circadian rhythm, brain connectivity, cognition and biomarker changes are determined.

insomnia is a common sleep disorder characterized by difficulty in starting or maintaining sleep, or poor sleep quality and shortened sleep time. the prevalence of insomnia is about 10-20% of population worldwide; of which about approximately 50% are chronic. insomnia is a risk factor for cognitive impairment and mental disorder development, and other diseases. non-pharmacological interventions, e.g. physio-therapy, are often ineffective. benzodiazepines and their derivatives are commonly prescribed for those patients but their side effects and long-time residual sleepy actions are very risky. dexmedetomidine is a highly selective α2 adrenergic receptor agonist with sedative, analgesic and anti-anxiety effects together with remarkable cytoprotective effects. it is widely used as a sedative. dexmedetomidine was reported promote sleep. it can also modulate "clock" protein expression and hence afford a regulatory effects on the circadian rhythm. this randomised, double-blinded and controlled trial was designed to investigate whether dexmedetomidine can treat chronic insomnia patients. its effects on sleep quality and improvement, eeg and circadian rhythm, brain connectivity, cognition and biomarker changes are determined. all participants are randomly assigned to receive either dexmedetomidine (a 0.5μg/kg bolus injection for 10 minutes followed by 0.1µg/kg/hr) or placebo (normal saline infusion with an identical protocol as dex) for 8 hrs from 10pm to 6 am.

Eligibility criteria:
inclusion criteria: * age between 18- 65 years old * body mass index (bmi) between 18 and 35 kg/m\^2； * clinical diagnosis of chronic insomnia； * must be able to communicate with site personnel exclusion criteria: * clinical diagnosis of mental disorders; * pregnancy; * current use of psychotropic drug ; * clinical diagnosis of neurological diseases

Keywords: chronic insomnia dexmedetomidine circadian rhythm sleep monitoring brain functional connectivity
study of rivoglitazone in type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: this is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. the total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes * male or female at least 18 years of age * hemoglobin a1c \> 7% and less or equal to 8.5% * non-fasting c-peptide \> 0.5 ng/ml * current monotherapy treatment with stable dose of approved non-thiazolidinedione (tzd) antihyperglycemic medication for greater or equal to 3 months prior to screening or * untreated with any antihyperglycemic agent during 2 months prior to screening exclusion criteria: * history of type 1 diabetes or ketoacidosis * history of long-term therapy with insulin * body mass index (bmi) \> 45 kg/m\^2 * known history of congestive heart failure (chf) * impaired hepatic function * history of prior treatment failure with, or intolerance of, a tzd * contraindication to treatment with pioglitazone * treatment with fibrates * if untreated with oral antihyperglycemic, considered to have failed diet and exercise modification as the sole treatment for type 2 diabetes

Keywords: type 2 diabetes mellitus
quetiapine versus haloperidol in the management of hyperactive delirium

Conditions: Hyperactive Delirium

Summary: in population of intensive care unit (icu), most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies. the role of such agents in patients with hyperactive is not fully understood. this study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in the intensive care unit, and mortality in critically ill patients.

a common complication in the intensive care unit (icu) that has recently been identified is delirium. defining delirium as a "sudden deterioration in attention, awareness, and cognition, which is not explained by any pre-existing neurocognitive disorder, but because of another medical condition," the diagnostic and statistical manual of mental disorders (dsm-v) clarified the definition of delirium. a dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is quetiapine. the limbic system is overactive in delirium, which is one of its pathophysiologies. by obstructing the mesolimbic dopamine d2 receptors specifically, quetiapine may be able to regulate this hyperactivity. the objective of this study is to compare the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in icu, and mortality in critically ill patients. this research will not receive any grants, funding, or financial aid (not funded study). collaborators declare that they have no conflicts of interest.

Eligibility criteria:
inclusion criteria: * all patients who are diagnosed with hyperactive form of delirium during their icu stay using cam-icu tool (the confusion assessment method for the intensive care unit) exclusion criteria: * suspected substance-induced delirium * previous use of antipsychotics * known allergy or intolerance to the study drugs * pregnancy or breast feeding * acute renal injury * hepatic failure * inability to tolerate oral drugs

Keywords: critical care hyperactive delirium antipsychotics haloperidol quetiapine
microbe-host interaction relationship in patients with stroke-relatedpneumonia

Conditions: Stroke-related Pneumonia

Summary: this study intends to use a standardized cohort study to collect biological samples (including throat swabs, sputum and blood) from subjects eligible for inclusion, and use 16s dna / metagenomic sequencing and metabolome technology to explore the microbial-host interaction relationship of sap patients.

stroke-related pneumonia (sap) is the most common complication of acute cerebral hemorrhage, and it is one of the main causes of disease aggravation, prolonged hospitalization and costs, and even death. the traditional antibiotic model proved ineffective, and new prevention and treatment methods were urgently sought.this study intends to use a standardized and rigorous cohort study to collect biological samples (including throat swabs, sputum and blood) of eligible subjects, and to explore the microbial-host interaction relationship in patients with sap, which may provide new targets and new ideas for the prevention and control of sap.

Eligibility criteria:
inclusion criteria: * age: 18 years old; * stroke was confirmed by imaging; * within 48 hours of onset, the onset time cannot be determined from the last normal observation; * glasgow coma scale (gcs) 7-14; * sap by clinical symptoms, laboratory examination or imaging confirmation, the modified cdc diagnostic criteria; * the patient (or his / her legal representative) signs a written informed consent form. exclusion criteria: * use of antibiotics within 4 weeks before stroke onset; * the presence of other conditions that may interfere with the follow-up and outcome assessment (such as known significant prestroke disability, mrs score of 3-5, end-stage malignancy, and liver and renal failure); * pregnant or lactating women.

Keywords: stroke-related pneumonia micropopulation
evaluation of respiratory muscle sarcopenia in obstructive sleep apnea syndrome

Conditions: Obstructive Sleep Apnea (OSAS)

Summary: osas is a disease characterized by repeated interruptions and restarts of breathing during sleep. respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. decreased respiratory effort is an important indicator of osas. age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. if osas is left untreated, it leads to cardiovascular diseases, dementia, alzheimer's and even death in early adulthood. in recent years, studies have shown that continuous positive airway pressure (cpap), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. there is no research in the literature on the evaluation of respiratory muscle sarcopenia in osas patients. this study aims to evaluate respiratory muscle sarcopenia in osas based on a concrete value reflecting respiratory muscle strength and/or volume.

in the study, respiratory muscle sarcopenia will be evaluated in osas patients. it will be evaluated whether the expiratory pressure value, peek flow meter value and 6-minute walking distance are predictors of respiratory sarcopenia for osas.

Eligibility criteria:
inclusion criteria: * diagnosed with normal-mild-medium-severe osas * 18 years and above * turkish speaking patients will be included. exclusion criteria: * pregnancy, * latent autoimmune diabetes, * chronic renal failure, * active or serious infections, * liver failure, * recent major cardiovascular events, * unstable angina, heart failure (nyha iii-iv), * patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests

Keywords: obstruktive sleep apnea sarcopenia respiratory muscle
a clinical trial to evaluate efficacy and safety of two different formulations of topical calcipotriol in patients with mild to moderate plaque psoriasis

Conditions: Mild to Moderate Plaque Psoriasis

Summary: this study is a phase iii, multicentre, randomized, observer blind, parallel group, three arms, controlled clinical trial to evaluate the efficacy and safety of topically applied calcipotriol/akvano 50 μg/g cutaneous solution against calcipotriol ointment 50 micrograms/g, sandoz and placebo in patients with mild to moderate plaque psoriasis

total 278 patients with mild to moderate plaque psoriasis were randomized into the study. study medications were applied twice daily for 8 weeks of study duration. patient's condition was assessed using of physician's global assessment (pga) and pasi scale. primary objective of this study is to assess the therapeutic equivalence of calcipotriol/akvano, 50 μg/g cutaneous solution with calcipotriol ointment 50 micrograms/g, sandoz based on pasi score.

Eligibility criteria:
inclusion criteria: * male or female patients (non-pregnant) of plaque psoriasis aged 18 to 65 years having either fitzpatrick skin type i-iii or iv-vi.\ * diagnosis of stable plaque psoriasis for 6 month by a dermatologist with lesions on arms, legs or trunk. * mild to moderate psoriasis on physician's global assessment (pga), * body surface area (bsa) involvement of 5-10% (both included) and pasi ≥ 5. * patients must be willing to provide written informed consent and willing to comply with study requirements exclusion criteria: * predominantly palmo-plantar, flexural, scalp and nail location of psoriasis * guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis. * patient with any uncontrolled systemic disease * patient with positive serology tests like hiv, hcv \& hbsag. * patient with presence of any skin disease that might interfere with the diagnosis or evaluation of the test medications. * patient with spontaneously improving or rapidly deteriorating plaque psoriasis. * use of systemic agents within four weeks prior to screening. * use of biologic agents within four weeks prior to study entry. * use of topical drugs that might alter the course of psoriasis or has received ultraviolet b treatment within two weeks prior to study entry. * use of phototherapy with psoralen ultraviolet a treatment within four weeks prior to study entry. * known sensitivity to any of the study treatments and/or study treatment's components. * need for surgery or hospitalization during the study * pregnant or nursing female patient or planning a pregnancy * concurrent involvement in any other clinical study within 30 days prior to entering the study
dry eye response to interval exercise and mediterranean diet

Conditions: Dry Eye; Diet Habit; Physical Inactivity

Summary: in the recent times, dry eye was found to be correlated sedentary life style, obesity, hypertension. so, changing the sedentary lifestyle is recommended

older patient who will complain from dry eye will be collected. it is planned to recruit 60 elderly (with obesity and hypertension) to be distributed into group 1 (this group will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus mediterranean diet) and group 2 (this group will receive only 3-time interval exercise per the week, applied for 30 min with high intensity). every group will contain 30 elderly

Eligibility criteria:
inclusion criteria: * elderly patients with dry eye complaints * the patients will be obese and hypertensives exclusion criteria: * heart or respiration problems * other diagnosed eye or systemic diseases
scoot: sample collection for dart

Conditions: Lung Cancer

Summary: the study will use a blood sample collected from participants to: * develop new ways of finding and diagnosing lung health problems, such as lung cancer. * develop tools which make it easier to screen people with possible lung health problems, diagnose problems earlier and with fewer tests, and start the best treatment faster. * help improve the early diagnosis of lung cancer, as finding lung cancer early means that it can be treated more easily and successfully.

the results from this study will be linked with the data from the dart study (also collecting data through the lung health check programme) to develop new ways of using computer technology (artificial intelligence) to improve lung health care. the studies use computer programs (called 'algorithms') which can be trained to analyse medical samples. once developed, these algorithms can be used to support doctors by increasing their speed and accuracy of diagnosing issues.

Eligibility criteria:
patient suitability will be assessed against the below criteria by the clinical teams managing the patients. inclusion criteria: 1. patients with a pulmonary nodule or nodule(s) detected on a ct scan performed as part of lung cancer screening from the lung health check centres, that require further investigation with a pet-ct scan, and / or biopsy, and / or resection 2. willing and able to give informed consent exclusion criteria: * none -

Keywords: screening lung health check artificial intelligence algorithm diagnosis detection
debio 1143-201 dose-finding and efficacy phase i/ii trial

Conditions: Squamous Cell Carcinoma of the Head and Neck

Summary: the use of multiple drugs in a single clinical trial or as a therapeutic strategy has become common, particularly in the treatment of cancer. because traditional trials are designed to evaluate one agent at a time, the evaluation of therapies in combination requires specialized trial designs. in place of the traditional separate phase i and ii trials, this trial uses a single phase i/ii clinical trial to evaluate simultaneously the safety and efficacy of combination dose levels, and select the optimal combination dose. therefore, this is a two part trial of debio 1143 combined with concurrent cisplatin and radiotherapy (crt) in participants with previously untreated stage iii, iva or ivb head and neck cancer. the trial begins with an initial period of dose escalation (phase i) to investigate the maximum tolerated dose (mtd) of debio 1143 that can safely be given in combination with crt. using the mtd determined in the phase i portion, the randomized phase ii trial in 94 participants compares debio 1143 to placebo, both with concomitant crt. the aim is to evaluate the efficacy and safety of debio 1143.


Eligibility criteria:
inclusion criteria: * meets protocol-specified criteria for qualification and contraception * is willing and able to comply with study procedures and restrictions related to food, drink and medications * voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures exclusion criteria: * has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters * has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff; 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3. the analysis of results
randomised ischaemic mitral evaluation (rime) trial

Conditions: Mitral Regurgitation; Coronary Artery Disease

Summary: the study is a randomised controlled trial comparing two treatment strategies for patients with moderate functional ischaemic mitral regurgitation undergoing coronary artery bypass grafting (cabg). patients will be randomised to receive either cabg alone or cabg plus mitral annuloplasty. the objective of the study is to determine if mitral annuloplasty in addition to cabg improves outcome in patients with moderate functional ischaemic mitral regurgitation.

70 patients with moderate functional ischaemic mr who are undergoing cabg will be recruited. patients will be randomised to undergo either cabg alone or cabg combined with mitral annuloplasty. patients will be investigated at baseline, 3 months and 1 year after surgery to determine functional capacity, quality of life, and cardiac function.

Eligibility criteria:
inclusion criteria: 1. patients undergoing cabg. 2. patients with moderate functional ischaemic mitral regurgitation without leaflet prolapse. exclusion criteria: 1. patients with severe lv dysfunction (ef less than 30%). 2. patients with associated significant aortic valve disease. 3. patients with significant co-morbidities: renal impairment (creatinine \> 160), liver impairment (inr \> 2.0, bilirubin \> 40), or underlying chronic obstructive lung disease (fev1:fvc ratio \< 0.6). 4. patients with nyha class iv symptoms, unstable angina, acute pulmonary oedema or cardiogenic shock. 5. patients unsuitable for surgery e.g. patients with advanced malignancy, unable to give informed consent. 6. patients with structural abnormalities of the mitral valve e.g. papillary muscle rupture, chordal rupture, etc. 7. patients with associated conditions which would significantly increase the risk of surgery. 8. patients who have had previous cardiac surgery. 9. patients with a previous history of endocarditis

Keywords: functional ischaemic mitral regurgitation